JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

MiR-302 targets PAK5 and prevents the transition from chronic hepatitis B to liver cirrhosis

  • 0Department of Laboratory Medicine, Hangzhou Normal University Affiliated Hospital, Hangzhou.
Jpma. the Journal of the Pakistan Medical Association +

|

December 11, 2024

|

December 11, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study found that p21-activated kinase 5 messenger ribonucleic acid and micro-ribonucleic acid 302 levels are elevated in patients with chronic hepatitis B and cirrhosis. These molecules show potential as biomarkers and therapeutic targets for liver disease progression.

Area Of Science

  • Hepatology and Molecular Biology
  • Biomarker Discovery
  • RNA Therapeutics

Background

  • Chronic hepatitis B (CHB) and liver cirrhosis are significant global health concerns.
  • Early detection and targeted therapies are crucial for managing liver disease progression.
  • Understanding the molecular mechanisms underlying liver damage is essential for developing novel treatments.

Purpose Of The Study

  • To quantify and compare serum levels of p21-activated kinase 5 messenger ribonucleic acid (PAPK5 mRNA) and micro-ribonucleic acid 302 (miR-302).
  • To investigate the roles and correlations of PAPK5 mRNA and miR-302 in the progression of chronic hepatitis.
  • To evaluate PAPK5 mRNA and miR-302 as potential biomarkers for CHB and liver cirrhosis.

Main Methods

  • An observational, case-control study involving 70 participants (healthy controls, CHB patients, and liver cirrhosis patients).
  • Serum samples were analyzed for PAPK5 mRNA and miR-302 expression using quantitative real-time polymerase chain reaction (qRT-PCR).
  • Clinical data and biochemical markers were retrospectively analyzed and compared between groups using SPSS 22.

Main Results

  • Serum PAPK5 mRNA levels were significantly higher in the cirrhosis group compared to CHB and healthy groups.
  • Serum miR-302 expression was significantly elevated in both CHB and cirrhosis groups compared to healthy individuals.
  • Clinical markers like albumin, platelet count, and aspartate aminotransferase/platelet ratio showed significant differences between patient groups.

Conclusions

  • PAPK5 mRNA and miR-302 are potential serum biomarkers for chronic hepatitis B and liver cirrhosis.
  • PAPK5 shows promise as a therapeutic target for liver disease.
  • miR-302 could be a therapeutic small molecule for liver fibrosis, contingent on effective delivery systems.

Keywords: